Abbott Devices Show Strong Early Trial Results

Abbott reports favorable 30-day outcomes for its SonicForce lithotripsy system and one-year data for its Amulet 360 occluder.

Updated on Nov. 2, 2026 in Heart Disease

Abbott Devices Show Strong Early Trial Results

Abbott Laboratories reported positive clinical trial results for two investigational cardiovascular devices. The company announced favorable 30-day outcomes from the TECTONIC study of its SonicForce Coronary Intravascular Lithotripsy System.

Why it matters

The results add clinical data for devices aimed at severely calcified coronary artery disease and non-valvular atrial fibrillation. Outcomes from early-stage investigational studies help inform how these technologies may be evaluated in the future.

The TECTONIC study enrolled 335 patients with severely calcified coronary artery disease, with a 97% procedural success rate and a 0.3% 30-day target lesion failure rate. Regulatory status and outcomes beyond the reported follow-up periods were not addressed in the source.

The players

Abbott Laboratories

Abbott Laboratories is a global healthcare company that develops medical devices, diagnostics and pharmaceuticals.

Transcatheter Cardiovascular Therapeutics

Transcatheter Cardiovascular Therapeutics is a major annual medical conference focused on catheter-based cardiovascular treatments.

The details

Abbott's SonicForce system uses acoustic pressure waves to fracture hard calcium deposits in narrowed vessels, and post-lithotripsy stent placement reduced remaining blockage to under 50% in all participants. The Amulet 360 platform, built on existing occlusion technology, features a softer, more conformable lobe and an outer disc that provides a secondary sealing layer.

Sunday: Abbott announced the TECTONIC SonicForce 30-day outcomes.
Monday: VERITAS Amulet 360 data was presented at the Transcatheter Cardiovascular Therapeutics conference in San Diego.

Health Landscape

Left atrial appendage occluders are a established device category for patients with non-valvular atrial fibrillation who need an alternative to long-term blood thinners. The Amulet 360 data add one-year outcome figures to this category, showing high rates of complete closure and low rates of major bleeding.

For people with atrial fibrillation or severe coronary calcification, these investigational devices represent possible future treatment options rather than available care today. Patients should discuss any device-based approach with their cardiologist, since the trial data do not establish availability or approval.

The takeaway

Early trial data can clarify how new heart devices perform, but approval and long-term results determine their role in care. Readers with heart conditions should rely on their own physicians for treatment decisions.